Big Ag just became humongous.

On 4 July, Bayer AG, the German multinational pharma company, bought the world’s most controversial agriculture company, Monsanto, in a $66-billion deal that gave Bayer control over a whopping 30% of the global seed market and a quarter of the pesticide market.

The merger, two years in the making, is part of a wave. US’ DowDupont and China’s ChemChina-Syngenta were formed through a merger in 2017. With Bayer-Monsanto (Bayer will later drop the Monsanto tag), 61% of the global seed and pesticide market will be in the hands of just three players. In 2016, there were six major rivals.

Indian seed companies, “small ag”, were alert, of course. So was the Competition Commission of India (CCI), the anti-trust regulator that monitors competition. The repercussions could be immense as agriculture drives India’s economy. The sector is closely monitored by outspoken activists like Vandana Shiva and Greenpeace, for whom corporate agriculture in general and Monsanto, in particular, represent corporate evil. They claimed that the merger could eliminate competition in certain markets and drive up seed and pesticide prices, making Indian farmers beholden to foreign corporate interests. In 2015, Monsanto, Bayer, or both, were dominant players in the Indian market for branded hybrid seeds of cotton, rice and at least 10 vegetable seeds. Bayer holds 40% of the hybrid rice market in India, for example.

“These are two very well positioned companies in India,” says David Spielman, senior research fellow at the International Food Policy Research Institute (IFPRI) in Washington, DC. “India and most other countries need to constantly be monitoring the effects of merger and industry consolidation on competitiveness and prices that farmers pay for these inputs.”

In May, CCI approved the merger with careful conditions. Bayer needs to sell a part of its herbicide and seeds business to an independent third party, and Monsanto needs to divest its 26% stake in Maharashtra Hybrid Seeds (Mahyco), a major Indian seed company. Bayer is planning to divest the businesses to Germany’s chemical company BASF, contingent on CCI approval. CCI has also asked Bayer to license on fair terms its digital platform that analyses agronomic data to recommend to farmers how best to use fertilizer, seeds and herbicides. It has asked Bayer to grant the government seven years of free access to agro-climatic data.

With CCI’s conditions in place, Indian seed and chemical companies are not very worried, according to interviews with industry executives. But perhaps they should be. Agriculture is undergoing rapid transformation to digital and Big Ag is helming that trend. In official-speak, CCI laid out its assessment thus: “Post combination, the Combined Entity’s [Bayer-Monsanto’s] transformation into a one-stop-shop platform, providing packaged solutions to the farmers in the seed and traits value chain and the agrochemical supply chain through their digital applications would lead to enhancement of its market power vis-à-vis its competitors who may be unable to offer similar integrated services to the farmers… The Combined Entity would enable more data capture, the ability to spread development costs and allocate more resources to simply out-spend smaller competitors.

AUTHOR

Gayathri Vaidyanathan

Gayathri writes on health, environment and science. She has reported and produced stories for the Washington Post, Discover, Nature, and the New York Times, amongst other publications. In her last assignment, she was the lead science writer for E&E News in Washington, D.C. E&E News is a news organisation focused on energy and the environment. Over the past decade, Gayathri has travelled across North America, Africa and Asia on long-form reporting projects. She has a master’s in journalism from Columbia University and a bachelor's in biochemistry from McMaster University in Ontario. At The Ken, Gayathri will write on healthcare, the pharmaceutical business and the environment. Based in Bengaluru, you can reach her at gayathri at the rate the-ken.com

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.